BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium

Rhea-AI Summary

BioLargo (OTCQX:BLGO) announced that Dr. Marcus Gitterle presented multi-site clinical experience with ViaCLYR at the Boswick Symposium on January 28, 2026. The ~36-case evaluation across four clinics showed rapid wound fluid reduction, enhanced healing, strong antimicrobial activity, tunnel closure, and no reported adverse events.

Clyra's Copper-Iodine Complex Solution (Clyrasept) was cited as the active technology behind observed tissue improvements and increased adoption by participating clinicians.

Clinical Experience Presented at Boswick Symposium Shows Rapid Wound Transformation, Enhanced Healing, and Strong Antimicrobial Performance Across Multiple Wound Types

WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 18, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, today announced that clinical experience with ViaCLYR™, Clyra Medical Technologies' advanced wound irrigation solution powered by its proprietary Clyrasept™ technology, was presented on January 28 by Dr. Marcus Gitterle, a respected Key Opinion Leader in wound care, at the Boswick Symposium, held January 24-30 in Maui, Hawaii.

Dr. Gitterle, who serves as Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy for the Christus Santa Rosa Hospital System in San Antonio, Texas, and Co-founder and Chief Medical Officer of Wound Centrix LLC, presented clinical results from a multi-site evaluation involving approximately 36 cases across four wound clinics over a four-month period. The presentation highlighted outcomes across challenging wound care settings, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds.

The clinical experience demonstrated what Dr. Gitterle described as "remarkable" and "unusual" results, with ViaCLYR™ showing excellent safety, strong antimicrobial performance, and notably enhanced healing characteristics. Importantly, clinicians reported no adverse reactions during the evaluation period, reinforcing ViaCLYR™'s favorable safety and tolerability profile.

ViaCLYR™ utilizes Clyra's proprietary Copper-Iodine Complex Solution (CICS), marketed as Clyrasept™, which is designed to provide rapid, broad-spectrum antimicrobial activity while remaining biocompatible. The presentation detailed several key clinical observations that exceeded initial expectations:

• Very rapid reduction in wound fluid discharge

• Noticeable increase in healing activity early in treatment, with improved tissue quality

• Rapid closure or shortening of wound tunnels, a particularly challenging complication

• Improved wound edge appearance and new skin formation

• Dramatic wound transformation from chronic, scarred wounds to actively healing wounds

• Significant wound shrinkage and reduction in wound depth, particularly in pressure injuries

Clinical Perspective from Dr. Marcus Gitterle:

"In our multi-site clinical experience involving approximately 36 cases across diverse wound etiologies, ViaCLYR™ demonstrated clinically significant improvements in several wound characteristics, including enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction. Patients with chronic, fibrotic wounds showed rapid transformation to highly proliferative healing wounds-characteristics I found quite unusual given the severity of underlying disease and chronicity. Importantly, we observed no adverse events in our treatment population. The tissue effects we observed are likely related not only to very effective long-duration wound cleansing and biofilm suppression, but also to the beneficial effects of copper on healing processes. Because of the success of this evaluation, we are moving as a group to adoption of CICS as our wound care cleansing modality of choice."

- Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System; Co-founder and Chief Medical Officer, Wound Centrix LLC

"The clinical experience shared at the Boswick Symposium underscores what we designed ViaCLYR™ to achieve - effective antimicrobial support that works with the body, not against it," said Steve Harrison, Chief Executive Officer of Clyra Medical Technologies. "Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations, presented to a highly respected audience of wound care specialists, represents important validation as we continue our commercial rollout."

Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo, Inc., added, "Hearing clinicians describe transformative clinical outcomes-wounds transitioning from chronic and fibrotic to highly proliferative in remarkably short timeframes-is exactly what drives adoption in wound care. Dr. Gitterle's presentation reinforces the promise of Clyra's technology as we expand access to ViaCLYR™ and support the clinical community with evidence-based solutions."

Dr. Gitterle's presentation provided context on the scientific principles underlying the copper-iodine complex technology, which has been the subject of ongoing research and clinical evaluation in wound care settings.

The Boswick Symposium is a respected forum for advancing wound care knowledge, bringing together leading clinicians, researchers, and innovators focused on improving outcomes in complex wound management. Clinical insights shared at the conference contribute to broader understanding and evaluation of emerging technologies in real-world care environments.

Clyra Medical Technologies continues to support ongoing clinical evaluations and plans additional presentations and publications throughout 2026 as part of its commitment to evidence-based adoption and clinician education.

About Clyra Medical Technologies

Clyra Medical Technologies, Inc., a subsidiary of BioLargo, Inc., focuses on infection control and advanced wound care. Founded in 2012, the company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology. Clyra's product portfolio features FDA-cleared medical devices that leverage this patented technology to deliver superior wound care outcomes. The company continues to advance its research and development efforts, exploring expanded indications for its unique formulations and their synergistic applications with complementary wound care dressings and mechanical devices. Through strategic partnerships with leading distribution and marketing organizations, Clyra ensures its innovative products reach healthcare providers and patients who need them most.

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.

View the original press release on ACCESS Newswire

FAQ

What clinical results did BLGO's ViaCLYR show at the Boswick Symposium on January 28, 2026?

ViaCLYR showed rapid wound fluid reduction and enhanced early healing across ~36 cases. According to the company, clinicians reported improved tissue quality, tunnel shortening, significant wound shrinkage, and no adverse reactions during the multi-site four-month evaluation.

How many cases and wound types were included in the ViaCLYR clinical evaluation presented by BLGO?

The evaluation involved approximately 36 cases across four wound clinics over four months. According to the company, cases included diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds.

Did clinicians report any adverse events with ViaCLYR in the BLGO presentation?

Clinicians reported no adverse reactions during the evaluation period. According to the company, the multi-site experience noted excellent safety and tolerability while observing strong antimicrobial performance and tissue improvement in treated wounds.

What technology underlies ViaCLYR and how did it reportedly affect healing in BLGO's results?

ViaCLYR uses a Copper-Iodine Complex Solution (Clyrasept) designed for broad-spectrum antimicrobial activity and biocompatibility. According to the company, the technology aided biofilm suppression, wound cleansing, and contributed to faster granulation and sinus tract closure.

Will BLGO expand clinical evaluation and commercial rollout of ViaCLYR after the Boswick presentation?

Clyra plans continued clinical evaluations and additional presentations and publications through 2026. According to the company, the presenting clinicians are moving toward adopting CICS as their cleansing modality of choice while commercial rollout continues.